( ) COO Jessica Rousset tells Proactive Investors the drug manufacturing company has signed a deal with Canopy Growth Corp (TSX:WEED, NYSE:CGC), where Canopy will have an exclusive license to CURE's patented, multi-layer oral thin film technology for use with cannabis extracts and biosynthetic cannabinoids.

Rousset says the licence agreement allows CURE to accelerate and expand the impact of its technology by joining forces with Canopy, which has broad market access and resources to bring a product to market.